Mitochondria in cancer metabolism, an organelle whose time has come?

被引：49
作者：
Anderson, Rebecca G. [1 ]
Ghiraldeli, Lais P. [1 ]
Pardee, Timothy S. [1 ,2 ,3 ]
机构：
[1] Wake Forest Univ, Ctr Comprehens Canc, Dept Canc Biol, Winston Salem, NC 27109 USA
[2] Wake Forest Univ, Ctr Comprehens Canc, Sect Hematol & Oncol, Winston Salem, NC 27109 USA
[3] Rafael Pharmaceut, Newark, NJ USA
来源：
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2018年 / 1870卷 / 01期
关键词：
ACUTE MYELOID-LEUKEMIA; DIVISION INHIBITOR-1 MDIVI-1; CHRONIC LYMPHOCYTIC-LEUKEMIA; ADVANCED SOLID TUMORS; HUMAN OVARIAN-CANCER; DOSE-ESCALATION; PHASE-I; TARGETED INHIBITION; MUTANT IDH2; MOUSE MODEL;
D O I：
10.1016/j.bbcan.2018.05.005
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Mitochondria have long been controversial organelles in cancer. Early discoveries in cancer metabolism placed much emphasis on cytosolic contributions. Initial debate focused on if mitochondria had a role in cancer formation and progression at all. More recently the contributions of mitochondria to cancer development and progression have become firmly established. This has led to the identification of novel targets and inhibitors being studied as new therapeutic approaches. This review will summarize the role of mitochondria in cancer and highlight several agents under development.
引用
收藏
页码：96 / 102
页数：7
相关论文
共 75 条
  • [1] REDOX REGULATION OF FOS AND JUN DNA-BINDING ACTIVITY INVITRO
    ABATE, C
    PATEL, L
    RAUSCHER, FJ
    CURRAN, T
    [J]. SCIENCE, 1990, 249 (4973) : 1157 - 1161
  • [2] The Bcl-2 apoptotic switch in cancer development and therapy
    Adams, J. M.
    Cory, S.
    [J]. ONCOGENE, 2007, 26 (09) : 1324 - 1337
  • [3] Molecular dynamics simulations of the 30S ribosomal subunit reveal a preferred tetracycline binding site
    Aleksandrov, Alexey
    Simonson, Thomas
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2008, 130 (04) : 1114 - +
  • [4] Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
    Alistar, Angela
    Morris, Bonny B.
    Desnoyer, Rodwige
    Klepin, Heidi D.
    Hosseinzadeh, Keyanoosh
    Clark, Clancy
    Cameron, Amy
    Leyendecker, John
    D'Agostino, Ralph, Jr.
    Topaloglu, Umit
    Boteju, Lakmal W.
    Boteju, Asela R.
    Shorr, Rob
    Zachar, Zuzana
    Bingham, Paul M.
    Ahmed, Tamjeed
    Crane, Sandrine
    Shah, Riddhishkumar
    Migliano, John J.
    Pardee, Timothy S.
    Miller, Lance
    Hawkins, Gregory
    Jin, Guangxu
    Zhang, Wei
    Pasche, Boris
    [J]. LANCET ONCOLOGY, 2017, 18 (06) : 770 - 778
  • [5] Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
    Amatangelo, Michael D.
    Quek, Lynn
    Shih, Alan
    Stein, Eytan M.
    Roshal, Mikhail
    David, Muriel D.
    Marteyn, Benoit
    Farnoud, Noushin Rahnamay
    de Botton, Stephane
    Bernard, Olivier A.
    Wu, Bin
    Yen, Katharine E.
    Tallman, Martin S.
    Papaemmanuil, Elli
    Penard-Lacronique, Virginie
    Thakurta, Anjan
    Vyas, Paresh
    Levine, Ross L.
    [J]. BLOOD, 2017, 130 (06) : 732 - 741
  • [6] [Anonymous], 2017, BLOOD S1
  • [7] [Anonymous], 1898, ARCH ANAL PHYSL, P393
  • [8] [Anonymous], 1970, ORIGIN EUKARYOTIC CE
  • [9] Mitochondrial Dynamics - Mitochondrial Fission and Fusion in Human Diseases
    Archer, Stephen L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (23) : 2236 - 2251
  • [10] Resistance Is Futile: Targeting Mitochondrial Energetics and Metabolism to Overcome Drug Resistance in Cancer Treatment
    Bosc, Claudie
    Selak, Mary A.
    Sarry, Jean-Emmanuel
    [J]. CELL METABOLISM, 2017, 26 (05) : 705 - 707
12345678